Assignee
VISTERRA INC
US·37 granted patents·36 pending applications·106 citations·filing 2013–2025
Top patents by PatentIndex Score
73 records- 0197US11136385B2Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody moleculeVISTERRA INC·Filed 2020·Granted Oct 5, 2021·4 cites·38 claims
- 0297US10954296B2Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGAVISTERRA INC·Filed 2020·Granted Mar 23, 2021·4 cites·51 claims
- 0397US9212217B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Dec 15, 2015·14 cites·21 claims
- 0496US10968270B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 6, 2021·3 cites·30 claims
- 0596US9365639B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Jun 14, 2016·9 cites·30 claims
- 0693US10385123B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2018·Granted Aug 20, 2019·8 cites·30 claims
- 0793US8877200B2HA binding agentsVISTERRA INC·Filed 2013·Granted Nov 4, 2014·17 cites·9 claims
- 0892US10800835B2HA binding agentsVISTERRA INC·Filed 2018·Granted Oct 13, 2020·4 cites·20 claims
- 0992US10155806B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2016·Granted Dec 18, 2018·4 cites·30 claims
- 1092US9096657B2HA binding agentsVISTERRA INC·Filed 2014·Granted Aug 4, 2015·13 cites·30 claims
- 1191US2025066464A1Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2024·Application pending·0 cites
- 1289US11912781B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2022·Granted Feb 27, 2024·1 cites·10 claims
- 1389US11230593B2Compositions and methods for treating and preventing influenzaVISTERRA INC·Filed 2020·Granted Jan 25, 2022·4 cites·20 claims
- 1489US2024425569A1Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 1588US11059883B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2018·Granted Jul 13, 2021·2 cites·30 claims
- 1688US10513553B2Compositions and methods for treating and preventing influenzaVISTERRA INC·Filed 2016·Granted Dec 24, 2019·6 cites·22 claims
- 1787US10981982B2Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 20, 2021·1 cites·48 claims
- 1887US9969794B2HA binding agentsVISTERRA INC·Filed 2013·Granted May 15, 2018·7 cites·50 claims
- 1986US12297249B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Granted May 13, 2025·0 cites·13 claims
- 2086US12264203B2Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Apr 1, 2025·0 cites·13 claims
- 2184US12227587B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Feb 18, 2025·0 cites·10 claims
- 2283US12415865B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Sep 16, 2025·0 cites·2 claims
- 2383US12187807B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Jan 7, 2025·0 cites·4 claims
- 2483US11168131B2Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2016·Granted Nov 9, 2021·4 cites·15 claims
- 2581US2025059249A1Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 2680US12091451B2Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2021·Granted Sep 17, 2024·0 cites·18 claims
- 2778US12054539B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2021·Granted Aug 6, 2024·0 cites·20 claims
- 2876US11945868B2Antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2018·Granted Apr 2, 2024·1 cites·37 claims
- 2976US2025296982A1Engineered polypeptides and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3074US12024552B2Ha binding agentsVISTERRA INC·Filed 2020·Granted Jul 2, 2024·0 cites·19 claims
- 3174US2025043014A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3274US2024141334A1Binding polypeptides and methods of making the sameVISTERRA INC·Filed 2023·Application pending·0 cites
- 3373US2024301065A1Antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3471US12084484B2Interleukin-2 agents and uses thereofVISTERRA INC·Filed 2020·Granted Sep 10, 2024·0 cites·23 claims
- 3571US11773179B2Antibody molecules to C5aR1 and uses thereofVISTERRA INC·Filed 2021·Granted Oct 3, 2023·0 cites·4 claims
- 3671US2023365694A1IMMUNOSILENCING Fc VARIANTSVISTERRA INC·Filed 2022·Application pending·0 cites
- 3771US2025171555A1Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3871US2024342300A1Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3970US2024092921A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2023·Application pending·0 cites
- 4070US2019330326A1Antibody molecules to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2019·Application pending·0 cites
- 4170US2024376173A1Methods of using interleukin-2 agentsVISTERRA INC·Filed 2024·Application pending·0 cites
- 4269US2024383958A1Apelin receptor agonists and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 4368US2024366758A1Formulations of antibody molecules to dengue virusVISTERRA INC·Filed 2024·Application pending·0 cites
- 4467US2025382379A1Humanized antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 4566US12098178B2Methods of using interleukin-2 agentsVISTERRA INC·Filed 2021·Granted Sep 24, 2024·0 cites·31 claims
- 4666US2023416372A1IMMUNOSILENCING Fc VARIANTSVISTERRA INC·Filed 2023·Application pending·0 cites
- 4764US12338291B2Humanized antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2020·Granted Jun 24, 2025·0 cites·21 claims
- 4864US2022267418A1Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2021·Application pending·0 cites
- 4963US2017145086A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2016·Application pending·0 cites
- 5062US12202885B2Formulations of antibody molecules to influenza virusVISTERRA INC·Filed 2020·Granted Jan 21, 2025·0 cites·6 claims
Showing the top 50 of 73 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when VISTERRA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →